I take most of your points except the last one. The feedback would come in the form of publications, definitely from academia and to a lesser degree industry (admittedly a slow iteration time). Also just public discourse - there was no dearth of very specific, highly technical feedback for any of the releases of alphafold on twitter, for example.

But I can’t use this at all at work (a pharma company) because it would leak confidential information. So anything they learn from usage data is systematically excluding (the vast majority of?) people working on therapeutics.